Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PTUK Trading as: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PTUK
Primacor 1 mg/ml Solution for Injection.
| Pharmaceutical Form |
|---|
|
Solution for injection. Clear, colourless to pale yellow liquid. |
Each ampoule contains 1 mg/ml of the active substance Milrinone.
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Milrinone |
Milrinone is a positive inotrope and vasodilator, with little chronotropic activity. It also improves left ventricular diastolic relaxation. It is a selective inhibitor of peak III phosphodiesterase isoenzyme in cardiac and vascular muscle. It produces slight enhancement of A-V node conduction, but no other significant electrophysiological effects. |
| List of Excipients |
|---|
|
Lactic acid |
Type 1 colourless, glass ampoules 10ml or 20ml packed in lots of 10.
Not all pack sizes may be marketed.
Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PTUK
Trading as: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PTUK
PL 04425/0646
Date of first authorisation: 11 October 1989
Date of latest renewal: 7 April 2004
| Drug | Countries | |
|---|---|---|
| PRIMACOR | Brazil, Hong Kong, Malta, Mexico, New Zealand, Singapore, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
